vigencell hla-b5801
Search results
Scope
Date
~
-
Bio & Pharma
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment
ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFD...
Oct 25, 2024 (Gmt+09:00)
-
Bio & Pharma
ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe
ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...
Dec 27, 2023 (Gmt+09:00)
1
Latest News
- 1 TheBorn Korea eyes M&As, overseas expansion after planned $73.7 million IPO
- 2 Korea's Hana Bank to promote foreigners as managers in overseas units
- 3 Samsung to unveil 400-layer bonding vertical NAND for AI servers by 2026
- 4 Korean LPs sharpen focus on GPs' post-investment management
- 5 LG Energy Q3 profit more than doubles on higher sales